---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-007644"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:23:53.554627+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Odyssey Health signs exclusive worldwide sub-license for BreastCheck non-invasive breast test

## Summary
- Sub-license grants exclusive global marketing and distribution rights for BreastCheck, a 15-minute at-home test.
- BreastCheck is FDA registered in the US and registered in EU and UK; targets $26B breast cancer diagnostics market.
- Deal managed through subsidiary Odyssey Medical Devices; subject to closing conditions.
- CEO expects near-term commercialization and initial revenue, marking transition from development-stage to revenue-generating.
- No financial terms (upfront fee, milestones, royalties) disclosed in the filing.

## SEC filing metadata
- accession: 0001683168-25-007644
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316825007644/0001683168-25-007644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316825007644/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-007644
- JSON: https://secwatch.observer/filing/0001683168-25-007644.json
- Plain text: https://secwatch.observer/filing/0001683168-25-007644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.